| abstract |
This invention concerns compounds of formula (I), the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; R?1 and R2¿ each independently are hydrogen, hydroxy, halo, cyano, C¿1?-6alkyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar?1, Ar1C¿1-6alkyl, Ar?1oxy, Ar1C¿1-6alkyloxy; or when on adjacent positions R?1 and R2¿ taken together may form a bivalent radical; R?3 and R4¿ each independently are hydrogen, halo, cyano, C¿1?-6alkyl, C1-6alkyloxy, Ar?1¿oxy, C¿1?-6alkylthio, di(C1-6alkyl)amino, trihalomethyl, trihalomethoxy; R?5¿ is hydrogen, halo, cyano, optionally substituted C¿1?-6alkyl, C1-6alkyloxycarbonyl or Ar?1¿; or a radical of the formula -OR?10, -SR10, -NR11R12; R6¿ is an optionally substituted imidazolyl moiety; R7 is hydrogen or C¿1?-6alkyl provided that the dotted line does not represent a bond; R?8¿ is hydrogen, C¿1?-6alkyl or Ar?2CH¿2 or Het1CH2; R9 is hydrogen, C¿1?-6alkyl, C1-6alkyloxy or halo, or R?8 and R9¿ taken together may form a bivalent radical; Ar?1 and Ar2¿ are optionally substituted phenyl and Het1 is optionally substituted pyridinyl; having farnesyltransferase inhibiting activity; their preparation, compositions containing them and their use as a medicine. |